CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 598 enrolled
Drug / intervention
Pemetrexed +6 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00686959
NCT00686959Phase 3Completed
CompareCT.gov

Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other Than Predominantly Squamous Cell Histology

Eli Lilly and Company·interventional·Posted May 30, 2008·Updated Jun 28, 2016

In Brief

A Phase 3 clinical trial evaluating Pemetrexed, Cisplatin, and 5 other interventions for Non Small Cell Lung Cancer. Completed, enrolled 598 participants across 133 sites in 19 countries.

Detailed Summary

This study will compare the overall survival of participants with locally-advanced, Stage III Non-Small Cell Lung Cancer (NSCLC) with nonsquamous cell histology.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon Small Cell Lung Cancer
CountriesArgentina, Australia, Belgium, Brazil, Canada, China, France, Germany, Greece, India, Ireland, Netherlands, Portugal, South Korea, Spain, Taiwan, Turkey (Türkiye), United Kingdom, United States
Collaborators--

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 30, 2008
Enrollment StartSep 1, 2008
Primary CompletionOct 1, 2014
Study CompletionNov 1, 2014
TodayJul 2, 2026
Enrollment to primary: 6.1 yearsPosted 18.1 years ago

Interventions

Pemetrexeddrug

infusion over 10 minutes

Cisplatindrug

infusion over 60 minutes with adequate anti-emetic treatment and appropriate hydration per local practice guidelines

Etoposidedrug

administered per local practice guidelines over a minimum of 30 minutes

Vinorelbinedrug

administered over 6-10 minutes infusion per local practice guidelines

Paclitaxeldrug

administered as a 3-hour infusion

Carboplatindrug

administered per local practice guidelines over 30 minutes

Thoracic Radiation Therapy (TRT)radiation